Literature DB >> 8977275

Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter.

M M Simon1, L Gern, P Hauser, W Zhong, P J Nielsen, M D Kramer, C Brenner, R Wallich.   

Abstract

Plasmid DNA encoding the outer surface lipoprotein A (OspA) of Borrelia burgdorferi under the control of either strong eukaryotic/viral or its own bacterial promoter was injected intramuscularly (m. tibialis anterior) or intradermally into BALB/c and AKR/N mice. OspA-specific antibodies and OspA-reactive T helper 1 cells (Th1) were induced only with those plasmids containing the ospA structural gene including its own regulatory control region immediately upstream. In the absence of the ospA promoter, no or only marginal immune responses to OspA were obtained, even when strong eukaryotic promoter/enhancer elements were present. Together with the finding that the ospA promoter is active in a mouse B-lymphoma line, the data suggest that spirochetes are able to express at least part of their genes in the mammalian environment. Mice previously vaccinated with the relevant ospA plasmid DNA were protected against subsequent experimental challenge with a virulent strain of B. burgdorferi, as measured by the appearance of antibodies to a prominent protective epitope (LA-2) and the failure to re-isolate spirochetes from ear biopsies. In addition, C.B-17 severe-combined immunodeficient mice could be protected against infection by passive transfer of immune sera from ospA plasmid DNA-inoculated normal mice. Protective LA-2-related antibody titers obtained after repeated immunization persisted for 200 days and longer. This simple procedure of immunization using plasmid DNA consisting of a prokaryotic gene under the control of its own promoter holds great promise for the development of alternative subunit vaccines against bacterial infections, including Lyme disease. In addition, the availability of this novel prokaryotic promoter element now allows the study of the basis for the differential expression of bacterial genes in prokaryotic and eukaryotic environments.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977275     DOI: 10.1002/eji.1830261206

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.

Authors:  Mark R Scheckelhoff; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2005-11-04       Impact factor: 3.641

2.  DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.

Authors:  R Wallich; A Siebers; O Jahraus; C Brenner; T Stehle; M M Simon
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  M cell-targeted DNA vaccination.

Authors:  Y Wu; X Wang; K L Csencsits; A Haddad; N Walters; D W Pascual
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

4.  Borrelia burgdorferi-induced inflammation facilitates spirochete adaptation and variable major protein-like sequence locus recombination.

Authors:  J Anguita; V Thomas; S Samanta; R Persinski; C Hernanz; S W Barthold; E Fikrig
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

Review 5.  Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implications.

Authors:  G Wang; A P van Dam; I Schwartz; J Dankert
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

6.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

7.  Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine.

Authors:  Ghiabe H Guibinga; Bikash Sahay; Heather Brown; Neil Cooch; Jing Chen; Jian Yan; Charles Reed; Meerambika Mishra; Bryan Yung; Holly Pugh; Katherine Schultheis; Rianne N Esquivel; David B Weiner; Laurent H Humeau; Kate E Broderick; Trevor R F Smith
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.